Oramed Pharmaceuticals

Company Overview

Snapshot

Founded in March 2006 by Nadav Kidron and Miriam Kidron, Oramed Pharmaceuticals operates with 11–50 employees. The company has raised over $149.13 million across 10 funding rounds. In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, significant investment appreciation, and upcoming growth initiatives, including the launch of a new U.S. trial.

Business overview

Oramed Pharmaceuticals is a Health Tech & Life Sciences company focused on developing oral delivery solutions for drugs typically administered via injection. Its core technology, the proprietary POD platform, enables the oral administration of protein-based therapies. The company's flagship product is an oral insulin capsule, ORMD-0801, currently in advanced Phase 3 clinical trials for the treatment of type 2 diabetes. Oramed aims to serve the pharmaceutical and healthcare industries by transforming injectable medications into oral therapies, thereby improving patient experience and access to treatment.

Strategic signal

In October 2024, Oramed Pharmaceuticals announced a restructuring of its debt with Scilex Holding Company. This strategic financial maneuver indicates Oramed's active management of its investment portfolio and financial obligations, signaling a focus on optimizing its capital structure and potentially freeing up resources for its core pharmaceutical development activities, particularly its oral insulin program.

Company Intelligence Q&A

What is Oramed Pharmaceuticals' primary focus?

Oramed Pharmaceuticals focuses on developing oral delivery solutions for drugs that are currently administered via injection, utilizing its proprietary POD technology.

When was Oramed Pharmaceuticals founded and by whom?

Oramed Pharmaceuticals was founded in March 2006 by Nadav Kidron and Miriam Kidron.

What was a significant financial event for Oramed Pharmaceuticals in September 2023?

In September 2023, Oramed announced a $101,875,000 short-term senior secured note transaction with Scilex Holding Company.

What was the status of Oramed's oral insulin program in October 2025?

In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, significant investment appreciation, and upcoming growth initiatives, including the launch of a new U.S. trial.

What was the outcome of Oramed's Phase 2 clinical trial for ORMD-0801 for NASH in November 2022?

In November 2022, Oramed announced additional positive safety and efficacy data from its Phase 2 clinical trial of ORMD-0801 for NASH.